Seagen (SGEN) Tops Q4 EPS, Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seagen Reports Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023 4:02 PM EST-Total Revenues of $2.0 Billion in 2022, Including 23 Percent Annual Increase in Total Net Product Sales to $1.7 Billion-
-TUKYSA Granted FDA Accelerated Approval for Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer-
-ADCETRIS Received Pediatric Indication with FDA Approval for Children with Previously Untreated High Risk Hodgkin Lymphoma-
-Multiple Key Milestones Anticipated in 2023, including Potential Label Expansion, Key Data Readouts and Additional International Launches for Current Products-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS... More
